Attorney Docket No. 21402-665 (CURA 965)

Express Mail Label No.: EV473991466US Date of Deposit: September 6, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Landes et al.

SERIAL NUMBER:

10/805,177

EXAMINER:

Not Yet Assigned

FILING DATE:

March 19, 2004

ART UNIT:

1644

For:

S

ΒÎ

ANTIBODIES AGAINST T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN

DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF

Commissioner for Patents P.O. Box 1450 Washington, D.C. 22313-1450

TRANSMITTAL LETTER

Enclosed herewith for filing in the above-identified application please find the following documents:

- Revocation By Assignees and New Power of Attorney (1 pg) 1.
- 2. Schedule A (1 pg); and,
- 3. Return Postcard.

Although Applicants believe no additional fees are due with this submission, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 21402-665).

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Naomi S. Biswas, Reg. No. 38,384

Attorney for Applicants

c/o MINTZ, LEVIN Tel: (617) 542-6000

Fax: (617) 542-2241 Customer No. 55111

Dated: September 6, 2005

Attorney Docket No. 21402-665 (CURA 965)

EP 0 6 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSIGNEE:

CuraGen Corporation and Abgenix, Inc.

SERIAL NUMBER:

See Attached Schedule A

FILING DATE:

See Attached Schedule A

FOR:

See Attached Schedule A

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REVOCATION BY ASSIGNEES AND NEW POWER OF ATTORNEY

CuraGen Corporation and Abgenix, Inc., companies and owners ("Assignees") of the patents and patent applications listed on the attached Schedule A, hereby revoke any and all former powers of attorney and hereby appoint the attorneys and/or agents associated with Customer Number 55111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.

Please address all telephone calls to <u>Ivor R. Elrifi</u> at telephone number 617/348-1747. Please address all correspondence to Customer No. 55111.

The undersigned is authorized to act on behalf of the Assignees in the above-referenced patent applications.

Date

Spd 2md 2005

Respectfully submitted

George M. Yahwak

Director of Intellectual Property

CuraGen Corporation

Respectfully submitted,

Date: 8/24/05

Don Joseph

Senior Vice President and General Counsel

Abgenix, Inc.



Schedule A

U.S. APPLICATIONS

Assignment Reel and Frame Nos.	R#013168 F#0146	R# F#	R#015863 · F#0140
Application No.	10/041,860	10/665,383	10/805,177
Elling Date	January 7, 2002	September 16, 2003	March 19, 2004 10/805,177
	21402-661 Antibodies Directed To PDGFD and Uses Thereof CURA 961	21402-662 Method For the Treatment of Nephritis Using Anti-PDGF-DD CURA Antibodies 962	21402-665 Antibodies Against T-Cell Immunoglobulin Domain And CURA Mucin Domain 1 (TIM-1) Antigen and Uses Thereof 965
Docket No:	21402-661 CURA 961	21402-662 CURA 962	21402-665 CURA 965

TRA 2061200v1